Lantheus Sets Aside Its Annual Outlook As Curium Deal Awaits Antitrust Clearance

Third-quarter sales grew 1.5%, while reported and adjusted profits moved in opposite directions.

Share
Lantheus Sets Aside Its Annual Outlook As Curium Deal Awaits Antitrust Clearance

Lantheus Holdings, which makes radioactive drugs for disease imaging and treatment, suspended its full-year 2026 outlook Thursday because of its pending Curium merger, according to its quarterly earnings announcement. The company reported $389.9 million in unaudited third-quarter revenue, up 1.5% from $384.0 million a year earlier, in an SEC filing accompanying the results.

Cash Now, Milestones Later

The merger agreement announced August 3, 2026 would give shareholders $102.50 per share in cash at closing. Curium US Holdings would buy all outstanding Lantheus shares in a transaction valued at up to approximately $8.0 billion, which Lantheus' board unanimously approved.

Shareholders would also receive non-transferable rights to as much as $12.00 per share in additional cash, contingent on specified commercial milestones for Lantheus products through 2030. The maximum consideration is $114.50 per share; the milestone portion is potential payment, not guaranteed cash.

The Federal Trade Commission extended the merger's antitrust waiting period on October 21, 2026. Lantheus attributed the forecast suspension to the pending transaction and said it would skip its usual third-quarter earnings conference call.

Two Different Profit Pictures

Reported net income fell 19.4% to $22.4 million from $27.8 million a year earlier. Diluted earnings per share were $0.33, versus $0.41. Adjusted net income moved the other way, rising 34.3% to $115.1 million from $85.7 million, with adjusted diluted earnings of $1.68 versus $1.27.

The same split appeared in operations: reported operating profit declined 26.2% to $32.2 million, while adjusted operating profit increased 28.1% to $153.2 million. The adjustments excluded a $31 million intangible-asset write-down, stock and incentive pay, amortization and acquisition-related items, among other entries.

Cash generation offered another measure of the quarter. Operating cash flow was $102.0 million, and free cash flow—operating cash after capital spending—was $99.9 million. Cash and equivalents stood at $683.6 million at September 30, 2026, versus $359.1 million at December 31, 2025; Lantheus also had access to up to $750.0 million through a revolving credit line.

Neuraceq Grows, Pylarify Slips

Lantheus sells mainly to hospitals, independent imaging centers and government facilities in the United States. Its imaging products include Pylarify for prostate-cancer PET scans, Neuraceq for Alzheimer's disease and Definity for clearer heart ultrasound images.

Pylarify remained the biggest of those products, generating $238.9 million in quarterly sales, down 0.7% year over year. Neuraceq sales rose 123.0% to $45.6 million, while Definity brought in $85.7 million, up 4.8%. Pylarify TruVu received temporary Medicare payment status and a permanent billing code effective October 1, 2026, supporting its previously announced phased geographic launch.

The FDA approved Tauklaryfy, an imaging agent for adults with cognitive impairment being evaluated for Alzheimer's disease. Lantheus is assessing broader commercial availability while continuing to support Alzheimer's therapeutic programs through its Pharma Solutions business.

Bravnetsa received final FDA approval for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The agency determined it to be bioequivalent and therapeutically equivalent to Lutathera, and Lantheus is preparing its commercial launch.

Lantheus has also dosed the first patient in its investigational prostate-cancer imaging trial. The late-stage portion is expected to enroll approximately 400 participants to assess diagnostic performance, safety and tolerability.

Sources

More on Lantheus Holdings

All Lantheus Holdings (LNTH) coverage →